Delaware | 001-12465 | 91-1533912 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 4.01 | Change in Registrant’s Certifying Accountant. |
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit Number | Description | |
16.1 |
Dated: August 2, 2018 | CTI BIOPHARMA CORP. | |||||
By: | /s/ David H. Kirske | |||||
Name: David H. Kirske | ||||||
Title: Chief Financial Officer |
$]< MT#2;KX=6&G[)]!NK*ULY[>XDS:,\R[F>-7 WRLS2;F925)QSOQ<^'_A[QY\2 MOVE=)O/"$WB+79_#NDC13:Z:]P\5\]M="*2.15*P2"41'S6*8 R6VJV/MFN9 MT7X=Z-X?\:^(/%=G'<+K.O1P17\CW,CQR+ &$6(R=J;0[#*@9SSF@#Y2\2?# MSQK)X2^-_A7Q5I.J>(?&FMV-B_A+Q)86DLD;3QV$4=N!Y86:: B3&Q=P+,N"18\/>'/$.BZCIU]_P (IK$G@W3?BKK6I:MI*Z/. MLDMI/%.EE=QVYCW3Q1S21R8C#8(5\93(^T** /B8?"F__P"%C>%[J^\+:A=^ M#;GXGW^JZ?I\FCS2KI^ERZ+/#*TJ>63!#+?.6\MPH.\,5P3CVK]E'P^=$^&_ MB70[C0[K1M/C\6^(#9Z;?:=):1BQFU*XDMQ''(BCRFBD4@*,8...17M]% 'Q M-\&?"VM^#M,^!AU/P7K$?AWP_'K.G>(+(:+,7MM3DV?9;LP",O.@C2:(3QJR MCSQ\V-Q7V;X(^%-;\&_ WQ79W6D7D]O+J6N7>@^'GE:VGCTV2XF:SM%)PT&8 MRH53@QAU7"E<#W.B@#\_X]!U&+0/'*VFA>+O!^FZE\';3389K3P] X@4JGW4A@R3MR/N?QEX-T?X@>&KW0-?L_M^DW M@430"5XB2KAT970AD9656#*005!!!%4?!_PXT?P02]E+JM] N;5XO"7A MV.YDM]1N)LW+7%NT#R1&XB,0,P52#!\[#J,[6?AY=/XTU/PIXM\,^.K[2M1T M_1%\.WFE6\5YY(MH(P;:YU 1,UK+% 2H+2K#<20RE5!/R!@#LX\*UW MX57-_P")])FO/"&H7_@^]^+!U73M-FT6>86>F/I3Q7;R1>63!!->,[&-PH;? MN(PQK[:HH \-_:%\,7GAWX9>#-/\)^&I;_PKH>OZ6VJ^'=%MM[/I$+8:.*W0 M9D5&$+F)0=RQLN#G!\-\7^&YM3TWXTS:1X&\0):ZE\0O">NZ2@\,W<3S11_V M2;NXCC,(8%?(NRYV@_>!Y;!^Y** /E>ZT+Q38_&&^U?1]$O_ !7H5WJFH2SZ M/K>ERV5WI4_]GS1K6VYD,P*D;"!Y9!H6HVNB>+OLF@^*O". MG7_P:73(Y+/P] Z!KUG]NTJ\51-!YCQD[6#JRNA#*RLJL&4@@@$$$4 ?"GQ#TG2?B1X3^,&I1 M>#M7MO'VM>#+32M/\.IX*U*T9UM'(>6V>>U0R,7GA4K']Q(8 )= FMC%X1\/1W+P:C/,QNC<0- \D)N(FAS, F#!\[#@ MCZ.\'_#;1O!#>992:I?77EF);O6M6NM2G1"02B27$CLBDJI(4@,54G) -=30 M!\7:Q\.M0D\=:YX2\8>&O'&HZ3J%MH;>&;[2H8KQ8Q:VT(,%SJ/DL]K)%=0R M3&0NBMYQ89)(/N'[47@?4/$_P[M=>\/Z<=3\7^#=2MO$VC6T:@R7$MNV9;=? M4S0&:(#^\ZGL*]AHH ^9_A#\(?$/ACXF:[I.LZ+;Q^##J/\ PG=J\4:F*'4; MR.2*6P4 8<1.)YMP& =^"? <^DV/PDO[OP/JW]F:%\2O%,]Q:MH$[ M2V]G=C5OL UP^-B[E+%=I(^W** /B/1? TT&I^'M>C\%ZQ%K\7Q MEU/4FU%O#]TMS'I M K.#4[;4(;*S>\:SOI8XOLUT\"*SLNU+B+ " M_&OPJU75O#6I77AZRUOQ2FFP#39;J72+"XG5M+AD4*S0($0E=^%B#*K%",#, M^%_@"]TBY^!VJV_@[5=,\16OB[Q/_:>HSZ! 0>-IQ]P44 ?".B_#R;7O@[J\6N^"O&W_"QM%\%:IH>I1WNDHMG=7$T.U_*> M& ?VB9;B*.5&S(5R79E8D-]4_ 7P7HO@_P"&FB-I>@1Z!>:A96MQJ:&R-K<3 M72V\<;O.K*KF3Y "7&3C)S7HM% !1110 4444 %%%% !1110 4444 9WB.^O M],\/:I>:7IC:UJ=O:RS6NFK.L!NY50E(1(_RIO8!=S<#.3P*\+_X7A\=?^C: MKS_PMM+_ ,:]R\3W^HZ5X:U:]T?2_P"W-7MK2::STO[0MO\ ;)E0F.'S6^6/ M>P"[SPN UM/Y;>7)+P?D5L$\' M@=#TKIZKZAI]KJUC<65];0WEG<(8IK>XC$D DWNK"YCMXY+=)$$-VI/VB E1*ID^97=@5&U<; MY^+>JI\9_!JV'C274=&U?QQJ_AN\^T3) OD06-TPMX[7YAB&>W0?:LH\C$_* MR.IKZ6'P_P#"XT0Z,/#>D#2#*LYT_P"PQ?9S(I!5_+V[=P*J0<9&!Z4C_#[P MM)JK:H_AK2&U-KF.\:]:PB,QG12J2E]N=ZJS -G(!(!YH ^0OA7\0;SPM\._ MAQH )I<22 @AG:$@-\Q![+P[=> M-=>^(7P[\&ZI\4KW5;34O"NORWNI^'4AMQ